Septerna, Inc. Files S-1/A for IPO

Ticker: SEPN · Form: S-1/A · Filed: Oct 24, 2024 · CIK: 1984086

Sentiment: neutral

Topics: ipo, sec-filing, pharmaceutical

TL;DR

Septerna IPO filing updated. Looks like they're serious about going public.

AI Summary

Septerna, Inc. filed an S-1/A amendment on October 24, 2024, for its initial public offering. The company, incorporated in Delaware, is seeking to register its securities under the Securities Act of 1933. Its principal executive offices are located at 250 East Grand Avenue, Suite 65, South San Francisco, California.

Why It Matters

This filing indicates Septerna, Inc. is moving forward with its plan to become a publicly traded company, which could provide it with capital for further research and development in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — As an S-1/A filing, it represents a company seeking to raise capital through an IPO, which inherently carries market and execution risks.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this S-1/A filing?

This S-1/A filing is an amendment to Septerna, Inc.'s registration statement for its initial public offering (IPO), indicating updates or revisions to the previously submitted documents.

When was this amendment filed?

This amendment was filed with the SEC on October 24, 2024.

Where is Septerna, Inc. headquartered?

Septerna, Inc.'s principal executive offices are located at 250 East Grand Avenue, Suite 65, South San Francisco, California, 94080.

Who is listed as the President and CEO of Septerna, Inc.?

Jeffrey Finer, M.D., Ph.D. is listed as the President and Chief Executive Officer of Septerna, Inc.

What is the company's Standard Industrial Classification (SIC) code?

Septerna, Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 4,319 words · 17 min read · ~14 pages · Grade level 15.9 · Accepted 2024-10-24 07:51:34

Key Financial Figures

Filing Documents

Risk Factors

Risk Factors 14 Special Note Regarding Forward-Looking Statements 94

Use of Proceeds

Use of Proceeds 97 Dividend Policy 99 Capitalization 100

Managements Discussion and Analysis of Financial Condition and Results

Managements Discussion and Analysis of Financial Condition and Results of Operations 105

Business

Business 124 Management 181

Executive Compensation

Executive Compensation 194 Page Director Compensation 208 Certain Relationships and Related Party Transactions 211 Principal Stockholders 215

Description of Capital Stock

Description of Capital Stock 219 Shares Eligible For Future Sale 225 Material U.S. Federal Income Tax Considerations For Non-U.S. Holders of Common Stock 227

Underwriting

Underwriting 232 Legal Matters 244 Experts 244 Where You Can Find More Information 244 Index to Financial Statements F-1 We have not, and the underwriters have not, authorized anyone to provide any information or to make any representation other than those contained in this prospectus, any amendment or supplement to this prospectus or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of our common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus, any amendment or supplement to this prospectus or any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside the United States. i Table of Contents MARKET AND INDUSTRY DATA Market data and certain other statistical information used throughout this prospectus are based on independent industry publications, governmental publications, reports by market research firms, including, but not limited to, Clarivate , or other independent sources that we believ

View Full Filing

View this S-1/A filing on SEC EDGAR

View on Read The Filing